Vertaling van "phase iii clinical development program " (Nederlands → Frans) :

Planned to initiate a Phase III clinical development program in chronic coronary heart disease in Q1 2011
Début d’un programme de développement clinique de phase III dans la maladie coronarienne chronique prévu

QAB149 (indacaterol), a bronchodilator in development for Chronic Obstructive Pulmonary Disease (COPD), has been shown in Phase III clinical trials to significantly improve lung function over the currently available treatments formoterol and tiotropium at three months of therapy.
QAB149 (indacatérol), un bronchodilatateur en développement pour traiter la bronchopneumopathie chronique obstructive (BPCO), a montré, dans des essais cliniques de phase III que, au bout de trois mois, il améliorait notablement la fonction pulmonaire par rapport aux traitements à base de formotérol et tiotropium disponibles actuellement.

Significant investments were made in the first quarter of 2010 in R&D, including post-marketing commitments for A (H1N1) pandemic vaccines as well as the late-stage Menveo and MenB clinical development programs.
Au premier trimestre 2010, des investissements lourds ont été réalisés dans la R&D, comprenant des engagements ultérieurs à la vente pour les vaccins contre la pandémie de grippe A (H1N1) ainsi que des programmes de développement clinique ultime pour les vaccins Menveo et MenB.

Project/ Potential indication/ Planned Current News update Compound Disease area submissions Phase AG0178 Major depressive disorder 2012 III - Sublingual Phase III program initiated May 2010
Syndrome de l’X fragile 2012 II - Début d’une étude pivot chez les adultes au T4 2010 AG0178 Maladie dépressive grave 2012 III - Programme de phase III pour administration sublinguale

Fragile X syndrome 2012 II AG0178 Major depressive disorder 2012 III - Sublingual Phase III program initiated May 2010
AG0178 Maladie dépressive grave 2012 III - Programme de phase III pour administration sublinguale

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Updated Phase III data presented at the American Society of Clinical Oncology (ASCO) meeting in May further demonstrated a significant delay in tumor progression in patients with metastatic neuroendocrine tumors of the midgut who were treated with Sandostatin LAR.
Des résultats de phase III actualisés et présentés en mai au congrès de l’American Society of Clinical Oncology (ASCO) ont confirmé que Sandostatine LAR, administré à des patients atteints de tumeurs neuroendrocrines métastasiques de l’intestin moyen, ralentissait considérablement la progression de la tumeur.

Phase III data demonstrating a significant delay in tumor progression in patients with metastatic neuroendocrine tumors of the midgut who were treated with Sandostatin LAR were published recently in the “Journal of Clinical Oncology”.
Le «Journal d’Oncologie Clinique» a publié récemment les résultats de l’étude de phase III confirmant que Sandostatine LAR, administré à des patients atteints de tumeurs neuro-endrocrines métastasiques de l’intestin moyen, ralentissait considérablement la progression de la tumeur.

Allied and Complementary Medicine Koninklijk Besluit Association des Chiropracticiens Belges Belgian School of Osteopathy (Wet) Beroepen in de Individuele Gezondheidszorg Bristish Medical Association Belgisch Staatsblad Complementary and Alternative Medicine Collège Belge d’Ostéopathie Council of Chiropractic Education Comité Européen de Normalisation/ European committee for Standardization Cumulative Index of Nursing and Allied Health Literature Centre for Reviews and Dissemination Debategraph Doctor in chiropractic Diplomed in osteopathy (USA: Doctor in osteopathy) Evidence Based Medicine European Council on Chiropractic Education European School of Osteopathy Flanders International College of Osteopathy Fonds voor Wetenschappelijk Onderzoek Facilitated Positional Release Graduate Education Program Groupement National Représentatif des Professionnels de l’Ostéopathie/ Groepering, Nationaal en Representatief van de Professionele Osteopaten Grading of Recommendations Assessment, Development and Evaluation High Velocity Low Amplitude International Academy of Osteopathy Intervalle de confiance/betrouwbaarheidsintervallen International Chiropractors Association Institut William Gardner Sutherland Muscle Energy Techniques Mean Weighted Difference National Institute for Health and Clinical Excellence Nederlands Register voor Osteopathie Non Steroidal Anti-inflammatory Drug Organisation Mondiale de la Santé Wereldgezondheidsorganisatie World Health Organisation Beroepscompetentieprofiel Physiotherapy Evidence Database Proprioceptive Neuromuscular Facilitation
Association Belge des Ostéopathes Classique / Belgische Associatie van Klassieke Osteopaten America Chiropractic Association Anglo-European College of Chiropractic Allied and Complementary Medicine Arrêté Royal Association des Chiropracticiens Belges Belgian School of Osteopathy (Wet) Beroepen in de Individuele Gezondheidszorg Bristish Medical Association Complementary and Alternative Medicine Collège Belge d’Ostéopathie Council of Chiropractic Education Comité Européen de Normalisation European committee for Standardization Cumulative Index of Nursing and Allied Health Literature Centre for Reviews and Dissemination Debategraph Doctor in chiropractic Diplomed in osteopathy (USA: Doctor in osteopathy) Evidence Based Medicine European Council on Chiropractic Education European School of Osteopathy Flanders International College of Osteopathy Fonds National de le Recherche Scientifique Facilitated Positional Release Graduate Education Program Groupement National Représentatif des Professionnels de l’Ostéopathie/ Groepering, Nationaal en Representatief van de Professionele Osteopaten Grading of Recommendations Assessment, Development and Evaluation High Velocity Low Amplitude International Academy of Osteopathy Intervalle de confiance International Chiropractors Association Institut William Gardner Sutherland Moniteur Belge Muscle Energy Techniques Mean Weighted Difference National Institute for Health and Clinical Excellence Nederlands Register voor Osteopathie Non Steroidal Anti-inflammatory Drug Organisation Mondiale de la Santé Profil de compétences professionnel Physiotherapy Evidence Database Proprioceptive Neuromuscular Facilitation Randomised Controlled Trial Roland Morris Disability Questionnaire